A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) +/- linrodostat mesylate, followed by adjuvant postsurgical NIVO +/- linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
Document type:
Meeting Abstract
Author(s):
Sonpavde, Guru; Necchi, Andrea; Gupta, Shilpa; Steinberg, Gary D.; Gschwend, Juergen; Van der Heijden, Michiel Simon; Richiero, Audrey; Lambert, Alexandre; Raybold, Bradley; Gajavelli, Srikanth; Zardavas, Dimitrios; Galsky, Matt D.